Clinical Study

Allovir For Kidney Transplant Patients With Bk Virus

Posted Date: Mar 1, 2021

  • Investigator: Ervin Steve Woodle
  • Specialties:
  • Type of Study: Drug

This multicenter, randomized, double-blind, placebo-controlled, multiple dosing interval, 3-period study of the safety, tolerability and effectiveness of adoptively transferred Viralym-M multivirus-specific T cells in kidney transplant recipients with low titers of BK viremia. The primary objective is to assess the safety and tolerability of Viralym-M and to test the hypothesis that administration of Viralym-M to kidney transplant recipients with BK viremia will demonstrate superiority in suppressing BK viral load compared with placebo.


Kidney Transplant Recipient With Bk Virus In The Blood


Kidney Transplant, Bk Virus

For More Information:

Amanda Naciff Stahl

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.